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Introduction
The aging of populations worldwide in the coming decades
will lead to a marked increase of age-related diseases and
disability with consequent profound personal, social and
economic implications (1, 2). Given the difficulty in reversing
aging’s disabling cascades, it is important to act preventively
with specifically tailored interventions against prodromal signs
of disease and disability when these processes are still
amenable to effective modification.
Recently, the frailty syndrome, which renders individuals
more vulnerable to adverse health outcomes through generally
subtle and progressive physical changes, has attracted  attention
in the medical and scientific communities as well as within the
public health departments of numerous countries (3). In fact
acting on frailty through effective interventions may change the
aging trajectories of many individuals from the possible
“pathological aging” pattern to the more personally and
economically desirable “successful aging” (4).
With regard to the brain, the role of brain aging, the
development of brain frailty (i.e. a state of reduced
neurophysiological reserves) and their relationship to both the
late-life appearance of neurodegenerative and vascular diseases
and to the appearance of physical frailty itself are not well
understood. Recent demographic changes in industrialized
populations have led to the emergence of the so-called
“dementia epidemic”. Available treatments for Alzheimer’s
disease (AD), for example, have only shown a moderate short-
term symptomatic effect without any disease-modifying
efficacy. Moreover, several promising new drugs based mainly
on the amyloid hypothesis have recently failed to alter
established disease in phase 3 clinical trials (5). As a
consequence, interest has developed in focusing on the
preclinical stages of the dementia syndrome and on the
identification of effective preventive strategies. Thus, similarly
to disability prevention, there is an urgent need to act early,
before neuronal damage becomes irreversible.
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Abstract: The frailty syndrome has recently attracted attention of the scientific community and public health
organizations as precursor and contributor of age-related conditions (particularly disability) in older persons. In
parallel, dementia and cognitive disorders also represent major healthcare and social priorities. Although physical
frailty and cognitive impairment have shown to be related in epidemiological studies, their pathophysiological
mechanisms have been usually studied separately. An International Consensus Group on “Cognitive Frailty” was
organized by the International Academy on Nutrition and Aging (I.A.N.A) and the International Association of
Gerontology and Geriatrics (I.A.G.G) on April 16th, 2013 in Toulouse (France). The present report describes the
results of the Consensus Group and provides the first definition of a “Cognitive Frailty” condition in older adults.
Specific aim of this approach was to facilitate the design of future personalized preventive interventions in older
persons. Finally, the Group discussed the use of multidomain interventions focused on the physical, nutritional,
cognitive and psychological domains for improving the well-being and quality of life in the elderly. The
consensus panel proposed the identification of the so-called “cognitive frailty” as an heterogeneous clinical
manifestation characterized by the simultaneous presence of both physical frailty and cognitive impairment. In
particular, the key factors defining such a condition include: 1) presence of physical frailty and cognitive
impairment (CDR=0.5); and 2) exclusion of concurrent AD dementia or other dementias. Under different
circumstances, cognitive frailty may represent a precursor of neurodegenerative processes. A potential for
reversibility may also characterize this entity. A psychological component of the condition is evident and concurs
at increasing the vulnerability of the individual to stressors.
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At present, the concept of frailty has focused principally on
the physical domain. However, some recent work has started
considering cognition in the definition of frailty (6, 7). For
example, a recent review paper by Clegg et al. included the
pathophysiological pathway of brain aging among the causal
factors of the frailty syndrome (8). Similarly, Buchman et al.
have suggested that the accumulation of common brain
pathological findings (e.g. Alzheimer’s disease pathology,
macroinfarcts, nigral neuronal loss) was independently
associated with the rate of progression of physical frailty
accounting for more than 8% of the variance unexplained by
demographic variables alone in older participants from the
Religious Orders Study and Memory and Aging Project (9). In
view of the increased interest in the frailty syndrome and its
relationship to the aging brain, and the continued goal of
developing strategies to improve disability in the elderly, a
workshop on Cognitive Frailty was conducted by an
International Consensus Group on the 16th of April 2013 in
Toulouse (France). The experts were chosen due to their
expertise in different fields including frailty, Alzheimer’s
disease, public health, and geriatrics. The experts were selected
by the Task Force chairs. A proposal paper was initially drafted
and sent to the Consensus Group members prior to the meeting.
The draft was presented and discussed during the meeting to
reach consensus and formulate recommendations. The draft was
revised after the meeting, resent to all co-authors for comments
and a final version was commonly accepted by all members and
the Task Force chairs. Discrepancies were discussed during the
meeting and a final proposal was agreed.
Primary aim of the meeting was to discuss current issues
related to the relationship existing between frailty and
cognition. Specific objectives of the meeting were: i) to
summarize the existing literature in order to identify the papers
that have examined whether frailty is capable to predict
cognitive outcomes, ii) to provide evidence showing links
between frailty and cognition, iii) to discuss and propose a first
definition on cognitive frailty, iv) to discuss and propose a list
of screening tools and specific clinical and biological markers
for identifying individuals at risk of physical disability and
neurodegenerative disease, and v) discuss and propose potential
preventive interventions about cognitive frailty.
Physical frailty and cognitive impairment have been studied
separately
Theoretical and operational definitions of frailty
Frailty is a multidimensional geriatric syndrome
characterized by increased vulnerability to stressors as a result
of reduced capacity of different physiological systems (10, 11).
It is also associated with increased risk of adverse health-
related outcomes including falls, disability, hospitalizations and
mortality (12-14). Although research on frailty has been
ongoing for the last 15 years, there is still a lack of consensus
about a unique operational definition (15-17). With progress in
the identification of biomarkers and other advances in
medicine, the definitions of diseases are constantly changing
e.g. Alzheimer’s disease, cancer, diabetes, and vascular
diseases. This may partly explain the discrepancies in the
prevalence rates of physical frailty, recently reported to vary
widely ranging between 4.0-59.1% among older adults aged ≥
65 years (8, 18). 
To translate the theoretical concept of frailty into practice,
several operational definitions of frailty have been proposed
and are currently available in the literature. These emphasize
principally physical frailty. For the purposes of this review, the
main definitions are presented. The most commonly used
definition of frailty was developed by Fried et al. as part of
their work in the Cardiovascular Health Study (CHS) (11) and
the Women’s Health and Aging Studies (WHAS) [10]. Frailty
is operationally defined as a clinical condition meeting 3 out of
5 criteria related to a physical phenotype including weak
muscle strength, slow gait speed, unintentional weight loss,
exhaustion and low physical activity (11). Although the
physical phenotype of frailty has been validated and used in a
number of studies (14, 15, 19, 20) many investigators have
suggested a broader multidomain phenotype of frailty which is
not limited strictly to the physical domain yet including diverse
syndromes, diseases and disability states. Thus, Rockwood et
al. operationalized the Frailty Index (FI) capturing the age-
related accumulation of clinical deficits, such as disability,
diseases, physical and cognitive impairments, psychosocial risk
factors and geriatric syndromes (such as falls, delirium and
urinary incontinence) (21). The same group also developed the
Clinical Frailty Scale based on 7 components ranging from 1
(robust health) to 7 (complete functional dependence on others)
in order to provide a more clinical friendly instrument for the
detection of frailty (7). Another operational definition of frailty
was more recently developed and validated by Ensrud et al. in
the Study of Osteoporotic Fractures (SOF) aiming to simplify
the definition proposed by Fried et al. (22). This new screening
instrument defines frailty as the presence of at least 2 out of 3
criteria including unintentional weight loss, inability to rise
from a chair and exhaustion (23). Furthermore, Gobbens et al.
have developed the Tilburg Frailty Indicator (TFI), a self-
reported questionnaire to assess frailty (24). The TFI defines
frailty including 3 domains (physical, psychological and social)
and 15 single questions in these 3 domains. The score ranges
from 0 to 15, with higher score indicating higher risk of frailty. 
Frailty has been predictive of poor clinical outcomes (e.g.
falls, disability, hospitalization, mortality) (25-28), and has
further been associated with biological abnormalities (e.g.
biomarkers of inflammation) regardless of the definition used to
assess frailty (29). These findings clearly suggest that frailty is
influenced by a number of pathophysiological modifications
involving the body’s diverse physiological systems.
Cognitive function in older persons
Current research suggests that dementia represents the last
phase of a progressive accumulation of pathological changes
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starting decades before the earliest clinical symptoms appear
(30).  In this regard, AD, for example, is actually considered as
a continuum of disease from preclinical asymptomatic to overt,
symptomatic stages. Aiming at properly capturing and
summarizing the course of the disease, several
concepts/definitions have been proposed, both in clinical (31,
32) and research settings (33), to differentiate the different
phases of the pathophysiological process (Table 1). These
definitions have incorporated the recent scientific advances in
the field, especially concerning biomarkers of the core features
of AD (cerebrospinal liquid Aβ42, Tau and phospho-Tau
concentrations; amyloid deposition and glucose metabolism in
positron emission tomography (PET); brain atrophy in
magnetic resonance imaging (MRI)). Despite some slight
discrepancies, there is a growing consensus in subdividing the
course of AD and dementia into three subsequent stages: 1) a
preclinical/asymptomatic stage, only revealed by biomarkers
evidence; 2) a predementia phase, characterized by the
impairment in memory or other cognitive domains not
negatively affecting social and/or occupational functioning; and
3) a dementia phase, in which cognitive disturbances
significantly interfere with the capacity for independent living.
In fact, the interventions so far investigated to reduce dementia
incidence have mainly failed, even if implemented in the Mild
Cognitive Impairment (MCI)/prodromal stage (34) (probably
because an extensive neuronal loss has already occurred).
Consequently, a strong effort is currently being developed to
more clearly conceptualize a “pre-MCI” phase. In this context,
a growing interest has emerged in “subjective cognitive
complaints” (SCC), defined as self- or informant-reported
cognitive disturbances occurring in the absence of an objective
impairment of cognitive performance (35). Despite some
conflicting results, SCC have been suggested as a potential risk
factor for the eventual onset of cognitive impairment and
dementia. Accordingly, dementia preventive trials (i.e. MAPT,
GuidAge) are increasingly enrolling participants with
subjective complaints as target populations (36, 37).
Nevertheless, several methodological issues (i.e. broad
heterogeneity of this entity, lack of standardized definitions and
limited assessment tools) have so far limited the clinical and
research adoption of the SCC concept. In conclusion, the
definition and operationalization of a cognitive premorbid
entity for dementia prevention is urgently needed.
Physical and cognitive functional decline are linked
Clinical and subclinical factors shared between frailty and
cognitive disorders
Multiple subclinical and clinical conditions seem to underlie
both the physical and cognitive age-related declines. For
example, depression has been related to hippocampal atrophy
and subsequent mild cognitive impairment (MCI) (38) as well
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Table 1
Currently adopted definitions of the different dementia/AD stages
Stage Definition Criteria
Dementia phase
All cause dementia Cognitive and neuropsychiatric symptoms that: 1) interfere with normal functioning; 2) represent a NIA-AA
decline from previous levels of performing; 3) are not explained by delirium or other major psychiatric 
disorders; 4) are detected by history-taking and objective cognitive assessment; 5) involve a 
minimum of two cognitive/behavioral domains (memory, reasoning, visuospatial abilities, language,
personality)
Dementia due to AD Dementia + evidence of AD biomarkers NIA-AA
AD dementia Dementia + evidence of AD biomarkers IWG
Predementia phase
Mild cognitive 1) concerns reflecting a change in cognition reported by patient or informant or clinician; 2) objective NIA-AA
impairment (MCI) evidence of impairment in one or more cognitive domains; 3) preservation of independence in functional 
abilities; 4) not demented.
Late MCI (LMCI) Concern on memory impairment  and objective memory performance of 1.5 SD below the normative mean ADNI
in a standardized test
Early  MCI (EMCI) Concern on memory impairment  and objective memory performance between 1.0 SD and 1.5 SD ADNI
below the normative mean in a standardized test
MCI due to AD MCI + evidence of AD biomarkers NIA-AA
Prodromal AD 1) impairment of cued recall in a memory task; 2) preservation of independence in functional abilities; IWG
3) evidence of AD biomarkers
Subjective cognitive 1) self- or informant-reported cognitive disturbances; 2) normal objective performance on No criteria
complaints/impairment standardized cognitive testing (or performance less than 1.0 SD)
(SCC or SCI)
Preclinical phase
Preclinical stage of AD No cognitive impairment on standard assessment + evidence of AD biomarkers NIA-AA
Asymptomatic at-risk No cognitive impairment on standard assessment + evidence of AD biomarkers IWG
stage of AD
NIA-AA: National Institute on Aging-Alzheimer’s Association; IWG: International Working; Group for New Research Criteria for the Diagnosis of AD (81); ADNI: Alzheimer’s;
Disease Neuroimaging Initiative (82); SD: standard deviation
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as to the development or worsening of the physical frailty
syndrome in older persons (39, 40). Similarly, cardiovascular
risk factors (e.g. diabetes, dyslipidemia, hypertension,
inflammation, hyperhomocysteinemia) may be responsible for
cumulative neurological damage (41-43) and are positively
associated with frailty (44-47). It has also been suggested that
genetic mutations (e.g. APOE4) as well as environmental
factors (e.g. low education, unhealthy dietary patterns, low
physical and mental activity, smoking, high alcohol
consumption) may negatively influence the aging brain (43, 48)
rendering it more fragile and exposing it to the development of
characteristic age-related diseases. Genetic (e.g. genes that are
involved in apoptotic and transcription regulation pathways
such as 5-methyltetrahydrofolate-homocysteine
methyltranferase (MTR), Caspase 8 (CASP8), CREB-binding
protein (CREBBP), lysine acetyltransferase 2B (KAT2B), and
beta-transducin repeat containing (BTRC) loci) (49), and
environmental factors (such as nutrition and physical activity)
are also strongly related to frailty, both physical (50-52) and
brain (53-55). Additional, pathophysiological mechanisms
including oxidative damage and functional changes in the
hippocampus and prefrontal cortex have been identified as
important factors potentially mediating cognitive decline and
potentially leading to dementia (56-58). Recently, Clegg et al.
have suggested that structural and functional changes in the
aging brain in combination with frailty may identify elderly
people at particularly high risk of adverse outcomes (8).    
Physical frailty and the added value of cognition
Cognitive impairment has increasingly been recognized as a
component of frailty, contributing to its heterogeneity (6, 59).
Interestingly, data from the French Three-City Study cohort,
among older individuals aged 65-95 years, have incorporated
cognitive impairment to the frailty phenotype and observed that
cognitive impairment improved the predictive validity of the
phenotype of frailty for adverse health outcomes over four
years of follow-up (60).
A comprehensive review was performed in order to identify
all relevant articles showing associations between the physical
and cognitive domain of frailty (Figure 1). A Medline literature
search of all articles published after 2001, when Fried et al.
developed the first operational definition of frailty, was
performed using the Medical Subject Heading (MeSH) terms
“Human”, “English”, “Aged 65+ years” combined with the
terms “Frailty” and “Cognition”. Overall, 232 articles were
retrieved. The identified abstracts were evaluated and for those
articles that met the inclusion criteria the full articles were
obtained in order to identify all relevant articles examining
whether frailty is predictive of cognitive status. The consensus
group had no interest at exploring the physical impairments due
to cognitive decline because the underlying pathways for such
relationship largely rely on neurodegenerative disorders and are
already well know. Alternatively, the aim was to discuss
current evidence potentially supporting a novel cognitive
condition caused by physical frailty. Such a nosological entity
is not yet described, but frequently identified in the assessment
of older persons with physical frailty. A final selection of 9
articles was used for the purpose of this review shown in Table
2.
Figure 1
Flow chart of retrieved and selected articles showing
associations between the physical and cognitive domain
A number of longitudinal studies have indicated that frailty
was associated with low cognitive performance over time in
older individuals with and without dementia (61-67) and cross-
sectional analyses, although limited, have also reported
associations between physical frailty and cognitive decline (68,
69). In the most recent prospective study, Gray et al. observed
that in a large population of older adults aged ≥ 65 years, frailty
was associated with a 2.57-fold increased risk for non-AD
dementia, although they did not observe any associations
between frailty and all-cause dementia or AD (66). Findings
from this study are contradictory and suggest that the frailty
phenotype may not be predictive for dementia. Moreover, there
was a considerable variability in participants’ age and on the
assessment of frailty, so it was difficult to draw direct
comparisons. In summary, to date, studies on frailty and
cognition are associational in nature and do not demonstrate
causal links. Further research is needed to elucidate the links
between physical frailty and cognitive performance.
The inclusion of cognition in the operational definition of
frailty may also be important for meeting the multiple
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pathophysiological mechanisms shared by both frailty and
neurodegenerative disorders (70). 
Physical and cognitive decline in frailty
An example of the close relationship between physical and
cognitive decline in older persons can be directly observed in
the clinical practice. Recently, the Gérontopôle of the Centre
Hospitalier Universitaire de Toulouse (France) in collaboration
with the University Department of General Medicine of
Toulouse (DUMG) and the regional health authority (Agence
Regionale de Santé of the Midi Pyrénées region, France) has
developed an innovative Platform for the Evaluation of Frailty
and the Prevention of Disability, thus integrating frailty into
clinical practice. After the first 6 months of operation and
evaluation of (n=160) older adults, data show that more than
half of the assessed frail individuals (52.9 %) presented a
Clinical Dementia Rating score (CDR) of 0.5 revealing  an
objective cognitive impairment (71). In fact, whereas some of
these patients are likely to present an early phase of a
neurodegenerative condition (not yet diagnosed), or show a
non-dementia more accelerated decline, it is possible that many
others may not experience a further cognitive decline (Figure
2). The need for distinguishing different risk profiles (in terms
of future health-related events) within a unique theoretical
definition of frailty is crucial in order to adopt the adequate
countermeasures and allow for the development of specific
personalized intervention programs. In this context, it is
noteworthy that physical impairment is often responsible for
increasing sedentary behavior and social isolation in older
persons. These two factors do not only concur at determining a
vicious cycle detrimental for the physical domain of the
individual, but may also explain a cognitive decline caused by
factors independent of a neurodegenerative condition that
should be treated differently. 
Panel discussion on the definition of Cognitive Frailty in
older adults
Older non-demented persons can be operationally
categorized into four groups according to their physical and
cognitive status. These groups include:
(i) Robust older individuals (i.e., no evidence of physical
frailty) without cognitive problems (i.e., normal brain
aging);
(ii) Physically frail older adults with normal cognitive
functioning (as indicated by a Clinical Dementia Rating
[CDR] equal to 0), including individuals with subjective
memory complaints;
(iii) Older adults with no physical frailty but already exhibiting
a cognitive impairment (CDR=0.5);
(iv) Physically frail older adults with cognitive impairment
(CDR=0.5).
The consensus panel was particularly interested at discussing
about this latter group (iv), in order to evaluate whether
cognitive impairment may be linked to physical impairment
rather than neurodegenerative disorders, consequently making
cognition a relevant part of the frailty syndrome.
Figure 2
Different trajectories of cognitive function according to specific
conditions
Proposed definition of cognitive frailty
After evaluating the current literature, the consensus panel
proposed the identification of the so-called “cognitive frailty”
as an heterogeneous clinical manifestation characterized by the
simultaneous presence of both physical frailty and cognitive
impairment. In particular, the key factors defining such a
condition include:
- Presence of physical frailty and cognitive impairment
(CDR=0.5);
- Exclusion of concurrent AD dementia or other dementias. 
The two defining criteria imply that cognitive frailty is
characterized by reduced cognitive reserve, but is different
from the physiological brain aging. At the same time, it is
noteworthy that, under different circumstances, cognitive frailty
may also represent a precursor of neurodegenerative processes.
A potential for reversibility may also characterize cognitive
frailty. A psychological component of the condition is evident
and concurs at increasing the vulnerability of the individual to
stressors.
The proposed definition addresses a current gap in the
existing literature, as it particularly allows the
conceptualization of a cognitive impairment due to the physical
domain of the individual and not to the presence of a
concomitant neurological disease (Figure 2). In other words,
this represents the first attempt to identify a clinical entity
including both physical and cognitive dimensions. In fact,
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dementia and disability are complex conditions and should be
not attributed to a single domain. The identification of
cognitive frailty in older persons may support the design of
preventive and/or rehabilitative interventions, for which
specific clinical settings might be amenable in the future.
Moreover, the paper mentioned Alzheimer disease more than
other forms of dementia since this is the most common type of
neurodegenerative disorder. However, it is not in the aim of the
consensus group to study neurodegenerative disorders but a
condition characterized by cognitive impairment due to
physical conditions. As a further clarification, the frailty
syndrome (although phenotypically driven by the physical
domain) is a systemic condition. By using the term “cognitive
frailty”, the consensus wanted to identify a condition of
cognitive impairment caused by physical conditions.
Development of adequate screening tools and specific
clinical and biological markers
In order to design effective interventions for cognitive
frailty, effective screening and diagnostic tools exploring and
identifying multiple domains/causes of frailty including
cognitive and psychological status need to be developed. In
addition to improved screening instruments, biomarkers for
improving the determination of the risk for physical impairment
rather than neurodegenerative disease (and vice versa) need to
be identified. This will provide us with the opportunity to better
detect the possible future health trajectories that a frail person
with cognitive impairment will follow. Consequently, this
differentiation will allow the design of better personalized
preventive or therapeutic interventions.
Possible biomarkers, clinical markers and imaging
techniques that could be used to characterize and eventually to
predict distinct age trajectories were suggested by the expert
panel and are presented in Table 3. This list does not aim to be
complete, accurate, or exhaustive, however it is only indicative
and provides a rough description of the usefulness of different
parameters/techniques in the assessment of physical and
cognitive outcomes. 
To identify cognitive frailty, the panel suggested that all the
frail subjects should perform a comprehensive cognitive
assessment exploring memory performance as well as other
cognitive functions (i.e. executive functions).  Several cognitive
tests and instruments were suggested such as speed of
processing test, the Montreal Cognitive Assessment test
(MoCA), the Mini Mental State Examination (MMSE) and the
Alzheimer’s disease Assessment Scale-cognitive subscale
(ADAS-Cog). After cognitive assessment, a complete physical
assessment should be performed, which would help to identify
which conditions are associated to physical impairment.
Physical assessment tools, such as gait speed, hand grip
strength and weight loss were also recommended (72). In
addition, nutritional assessment would help to identify any
dietary deficits, and a brief psychological assessment including
tools such as the Geriatric depression scale (GDS) will help to
identify any causes of reduction of energy level. Before
proceeding in more sophisticated diagnostic procedures
including imaging techniques, such as computed tomography
(CT) and magnetic resonance imaging (MRI), correction for
reversible conditions was suggested. Other diagnostic
techniques can be considered for research purposes. Actigraphy
(73) and accelerometer-based measures (74) may be of interest
for measuring both physical activity and behavioral patterns.
Dual energy X-ray absorptiometry scans (DEXA), may provide
supplementary information about body composition. Functional
magnetic resonance imaging (f-MRI), Diffusion tensor imaging
(DTI), tractography, and cognitive evoked potentials could be
particularly useful cognitive research tools.
Table 3
Possible biological, clinical, and imaging markers for
identifying risk of physical disability and neurodegenerative
disease
Physical Neurodegenerative 
disability disease
Biomarkers 
Inflammatory markers +++ +++
(e.g. CRP, IL-6)
Beta-amyloid protein (Aβ) - ++
APOEε4 genotype - ++
Anemia ++ ++
Serum Albumin ++ ++
Cholesterol ++ ++
Vitamin D status ++ ++
Clinical markers 
MMSE ++ +++
Executive tests + +++
ADAS-Cog - +++
CDR ++ +++
MoCA ++ +++
Gait speed +++ ++
Hand grip strength +++ ++
Weight loss +++ ++
Psychological marker: GDS ++ +++
Actigraphy +++ +++
Imaging 
Dual energy X-ray absorptiometry ++ ++
scans (DEXA)
Cerebral Computed tomography (CT scans) + +++
Cerebral Magnetic resonance imaging (MRI) + +++
Functional magnetic resonance imaging + +++
(FMRI)
Diffusion tensor imaging (DTI) + +++
Tractography + +++
Electrophysiological methods + +++
Cognitive evoked potentials + +++
- : not recommended,+: may be of use, ++ : suitable for use, +++ : recommended for use;
CRP: C-reactive protein; IL-6: Interleukin-6; APOEε4: Apolipoprotein E ε4 allele;
MMSE: Mini Mental State Examination; ADAS-Cog: Alzheimer’s disease Assessment
Scale-cognitive subscale; CDR: Clinical Dementia Rating; MoCA: Montreal Cognitive
Assessment; GDS: Geriatric Depression Scale
In parallel, usual physical frailty markers (such as weight
loss and gait speed) should be assessed in persons exhibiting a
cognitive decline, even if at early stages.
Some markers may be able to well capture both the risk of
future physical and cognitive declines, such as inflammatory
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biomarkers [e.g. C-reactive protein (CRP) and Interleukin-6
(IL-6)] (28, 75, 76-78). However, biomarkers predictive of both
types of decline may not be particularly useful in differentiating
whether a person is at higher risk of a future physical rather
than a cognitive decline (and vice versa). Other markers may
better serve at estimating the specific risk for one single
domain. For example, the beta-amyloid protein (Aβ) and the
apolipoprotein APOEε4 genotype are closely related to the
development of dementia and Alzheimer’s disease (79).
Potential preventive interventions
Including cognition in the definition of frailty and exploring
the different health trajectories that a frail person with
subjective cognitive impairment will follow is emerging.
Research in this direction will further inform public health
policies to implement evidence-based research findings to the
development of prevention plans and clinical trials. Initially, a
list of preventive interventions may be considered. These may
include promotion of physical activity, cognitive stimulation
and training, healthy dietary habits (e.g. the Mediterranean
diet), smoking cessation, promotion of emotional resilience,
active and socially integrated lifestyles, optimal daily sleep,
maintenance of optimal body weight, and metabolic control
(including control of dyslipidemia, diabetes and blood pressure)
(80). As a further step the causes of frailty need to be identified
to enable the implementation of multidomain interventions
based on evidence-based research and depending on
personalized needs. Evaluation of pharmacological therapy and
drug use are also recommended. Multidomain interventions
might prove useful if focused on the physical, nutritional,
cognitive and psychological domains in order to improve the
well-being and quality of life in the elderly. The promotion of
physical exercise, correction of nutrient deficiencies, potential
nutrient supplementation, and implementation of cognitive
training (including a psychological perspective at the same time
with other interventions) may be considered to more
comprehensively improve well-being and the quality of daily
life in older persons. These strategies may result ineffective if
focused on single components and, thus, failing to capture the
complexity of the phenomenon.            
Concluding remarks 
Cognitive frailty may represent a novel concept to consider
in the complex and heterogeneous scenario of frailty in older
persons. It is hoped that this initial discussion between experts
from clinical, research and industry fields may provide a
stimulus for development of new research in the field. The
consensus group proposed the hypothesis of a possible new
condition. There was no intention of operationalizing it,
because available data are still preliminary and far to be
conclusive. Aim of the consensus was indeed to stimulate
research in the field. A continued dialogue on this topic would
benefit investigators with an interest in cognitive frailty to
develop new studies with the aim to better understand this
condition. It is also important that future research in the field
may inform public health policies for the implementation of
prevention and treatment programs. 
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